Mineralys Therapeutics Statistics
Share Statistics
Mineralys Therapeutics has 64.88M
shares outstanding. The number of shares has increased by 26.46%
in one year.
| Shares Outstanding | 64.88M |
| Shares Change (YoY) | 26.46% |
| Shares Change (QoQ) | 26.15% |
| Owned by Institutions (%) | 91.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 153 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 6.43M, so 10.24% of the outstanding
shares have been sold short.
| Short Interest | 6.43M |
| Short % of Shares Out | 10.24% |
| Short % of Float | 13.67% |
| Short Ratio (days to cover) | 11.24 |
Valuation Ratios
The PE ratio is -3.36 and the forward
PE ratio is -3.82.
Mineralys Therapeutics's PEG ratio is
-0.04.
| PE Ratio | -3.36 |
| Forward PE | -3.82 |
| PS Ratio | 0 |
| Forward PS | 1.6 |
| PB Ratio | 3.12 |
| P/FCF Ratio | -3.59 |
| PEG Ratio | -0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.02,
with a Debt / Equity ratio of 0.
| Current Ratio | 14.02 |
| Quick Ratio | 14.02 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,486,470.59 |
| Employee Count | 51 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 16% in the
last 52 weeks. The beta is -0.31, so Mineralys Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.31 |
| 52-Week Price Change | 16% |
| 50-Day Moving Average | 14.02 |
| 200-Day Moving Average | 12.39 |
| Relative Strength Index (RSI) | 56.58 |
| Average Volume (20 Days) | 1,212,321 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -192.4M |
| Net Income | -177.81M |
| EBITDA | -177.77M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.66 |
Full Income StatementBalance Sheet
The company has 114.09M in cash and 0 in
debt, giving a net cash position of 114.09M.
| Cash & Cash Equivalents | 114.09M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -302.52M |
| Total Assets | 205.9M |
| Working Capital | 190.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -166.31M
and capital expenditures -96K, giving a free cash flow of -166.41M.
| Operating Cash Flow | -166.31M |
| Capital Expenditures | -96K |
| Free Cash Flow | -166.41M |
| FCF Per Share | -3.43 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
